Clin2
NCT07449793Possibly a fitRecruiting

PBC treatment response and long-term health outcomes

Primary Biliary Cholangitis (PBC)Primary Biliary Cholangitis

Part of Digestive system clinical trials.

This research study tracks how well Primary Biliary Cholangitis (PBC) responds to standard medication (UDCA) and what happens to patients' health over time. It may help doctors understand which treatments work best for different people.

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
3,000 people
Ages
18 years to 85 years
Study type
Observational

Who can take part

  • You are 18 years or older
  • You have been diagnosed with Primary Biliary Cholangitis (PBC) according to current liver specialist guidelines
  • You are currently taking ursodeoxycholic acid (UDCA) at a standard dose (about 13-15 mg per kg of body weight each day)
  • You do not have other liver diseases like hepatitis C, active hepatitis B, autoimmune hepatitis, primary sclerosing cholangitis, or liver cancer
  • You have not had any other cancer (except for liver or bile duct cancers)
  • You are not pregnant or breastfeeding during the study

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07149675Recruiting
Long-term study for primary biliary cholangitis patients

This study tracks patients with primary biliary cholangitis (PBC) over time to understand long-term outcomes. It aims to gather information that could improve care and management for people with PBC.

Beijing, Select A State Or Province
NCT04650243Recruiting· Phase 4
Testing whether lowering UDCA helps people with PBC

This trial looks at whether slowly reducing UDCA (a medication for primary biliary cholangitis) is safe and still helpful in people whose liver tests have improved. It may help some patients avoid higher doses if their disease is well controlled.

Beijing
NCT07282353Recruiting· Phase 3
Study of CS0159 for primary biliary cholangitis with poor UDCA response

This trial tests an experimental drug (CS0159) for people with primary biliary cholangitis (PBC) who either didn't respond well to or couldn't take the standard treatment UDCA. It aims to improve liver function and reduce symptoms.

Hefei, Anhui
NCT07122206Not yet recruiting
Combination treatment for primary biliary cholangitis

This study looks at how well two medicines, ursodiol and seladelpar, work together for people with primary biliary cholangitis (PBC), a liver disease. It may help doctors understand the best way to treat PBC and improve liver health.

NCT06591468Enrolling by invitation· Phase 2/Phase 3
Prednisone Plus Ursodeoxycholic Acid for PBC Patients

This trial tests adding prednisone (a steroid) to ursodeoxycholic acid (a bile acid medicine) for people with primary biliary cholangitis who have a specific type of liver inflammation. The goal is to see if the combination works better at controlling the disease than standard care.

Guangzhou, Guangdong
NCT07795151Not yet recruiting· Phase 1/Phase 2
Stem cell therapy for PBC not responding to standard treatment

This study tests a new treatment using stem cells from umbilical cord blood to help people with primary biliary cholangitis (PBC) who haven't gotten better with standard medication. It aims to improve liver function and reduce symptoms.

Beijing, Beijing Municipality

Hear when a new Primary Biliary Cholangitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.